Cargando…

Tumor Necrosis Factor-Blocker Dose Escalation in Rheumatoid Arthritis Patients in a Pharmacy Benefit Management Setting

INTRODUCTION: Dose escalation with tumor necrosis factor (TNF)-blockers is poorly characterized in pharmacy benefit management (PBM) settings. METHODS: This retrospective study used integrated pharmacy and medical claims from the PBM Medco to characterize dose escalation among rheumatoid arthritis (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blume, Steven W., Fox, Kathleen M., Joseph, George, Chuang, Chien-Chia, Thomas, Jessy, Gandra, Shravanthi R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680672/ https://www.ncbi.nlm.nih.gov/pubmed/23740359 http://dx.doi.org/10.1007/s12325-013-0034-3

Ejemplares similares

Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting
por: Bonafede, Machaon, et al.
Publicado: (2013)

The Economic Benefit of Remission for Patients with Rheumatoid Arthritis
por: Curtis, Jeffrey R., et al.
Publicado: (2022)

Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population
por: Bonafede, Machaon, et al.
Publicado: (2014)

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

High Body Mass Index is Associated with Shorter Retention of Tumor Necrosis Factor-Alpha Blocker Treatment in Rheumatoid Arthritis
por: Elalouf, Ofir, et al.
Publicado: (2021)

Tumor Necrosis Factor Alpha Blocker-Induced Erythrodermic Sarcoidosis in with Juvenile Rheumatoid Arthritis: A Case Report and Review of the Literature
por: Park, Su-Kyung, et al.
Publicado: (2017)

Estimation of Cachexia among Cancer Patients Based on Four Definitions
por: Fox, Kathleen M., et al.
Publicado: (2009)

Benefits of Exercise in Rheumatoid Arthritis
por: Cooney, Jennifer K., et al.
Publicado: (2011)

Impact of a specialty pharmacy benefit on rheumatoid arthritis medication adherence and functional status: a continuation study
por: Kozlicki, Miranda, et al.
Publicado: (2019)

Long-term direct and indirect economic burden associated with osteoporotic fracture in US postmenopausal women
por: Tran, Oth, et al.
Publicado: (2021)

Correction to: Long-term direct and indirect economic burden associated with osteoporotic fracture in US postmenopausal women
por: Tran, Oth, et al.
Publicado: (2022)

Predicting treatment response to IL6R blockers in rheumatoid arthritis
por: Nouri, Bako, et al.
Publicado: (2020)

Clinical and economic burden associated with cardiovascular events among patients with hyperlipidemia: a retrospective cohort study
por: Fox, Kathleen M., et al.
Publicado: (2016)

Application of a validated algorithm to estimate the effectiveness and cost of biologics for rheumatoid arthritis in the US pharmacy benefit manager context
por: Wu, Ning, et al.
Publicado: (2015)

Influence of tumor necrosis factor α in rheumatoid arthritis
por: Kulp, Werner, et al.
Publicado: (2005)

Transfusion burden in non-dialysis chronic kidney disease patients with persistent anemia treated in routine clinical practice: a retrospective observational study
por: Fox, Kathleen M, et al.
Publicado: (2012)

Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk
por: Quek, Ruben G W, et al.
Publicado: (2015)

Ulcerative necrobiosis lipoidica in the setting of anti–tumor necrosis factor-α and hydroxychloroquine treatment for rheumatoid arthritis
por: Fehlman, Jennifer Albus, et al.
Publicado: (2017)

Doctors’ preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment
por: Kuijper, T. Martijn, et al.
Publicado: (2017)

Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trial
por: Sigaux, Johanna, et al.
Publicado: (2017)

Benefits of wrist splinting in patients with rheumatoid arthritis
por: Sadura-Sieklucka, Teresa, et al.
Publicado: (2018)

Regulation of serum matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 following rituximab therapy in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor blockers
por: Klimiuk, Piotr Adrian, et al.
Publicado: (2014)

Anti‐Inflammatory and Antiarrhythmic Effects of Beta Blocker in a Rat Model of Rheumatoid Arthritis
por: Lin, Ting‐Tse, et al.
Publicado: (2020)

Adherence and persistence in patients with rheumatoid arthritis at an integrated health system specialty pharmacy
por: Peter, Megan E, et al.
Publicado: (2021)

Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis for Function and Pain is Affected by Rheumatoid Factor
por: Aberumand, Babak, et al.
Publicado: (2014)

Cost–utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting
por: Hallinen, Taru A., et al.
Publicado: (2010)

A Retrospective Study to Examine Healthcare Costs Related to Cardiovascular Events in Individuals with Hyperlipidemia
por: Henk, Henry J., et al.
Publicado: (2015)

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab
por: Negoescu, Andra F., et al.
Publicado: (2014)

A Potential Benefit of “Balanced Diet” for Rheumatoid Arthritis
por: Masuko, Kayo
Publicado: (2018)

Targeting transcription factors for therapeutic benefit in rheumatoid arthritis
por: Balendran, Thivya, et al.
Publicado: (2023)

Rheumatoid Arthritis: Refractory to Infliximab, a Tumor Necrosis Factor Inhibitor
por: Solehan, Hana Maizuliana bt, et al.
Publicado: (2011)

Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis
por: Leandro, Maria J
Publicado: (2009)

What Pharmacy Benefit Designers Need to Know About Perception and Reality: Never Forget the Elephant in the Pharmacy
por: Fairman, Kathleen A.
Publicado: (2008)

Impact of anti-citrullinated protein antibody on tumor necrosis factor inhibitor or abatacept response in patients with rheumatoid arthritis
por: Tymms, Kathleen, et al.
Publicado: (2021)

Restored and Enhanced Memory T Cell Immunity in Rheumatoid Arthritis After TNFα Blocker Treatment
por: Khanniche, Asma, et al.
Publicado: (2019)

Development of Rheumatoid Nodules after Anti-Tumor Necrosis Factor-α Treatment with Adalimumab for Rheumatoid Arthritis
por: Shin, Sungsik, et al.
Publicado: (2016)

Benefits of Switch from Oral to Subcutaneous Route on Adherence to Methotrexate in Patients with Rheumatoid Arthritis in Real Life Setting
por: Senbel, Eric, et al.
Publicado: (2021)

Erratum to: ‘Costs of treating cardiovascular events in Germany: a systematic literature review’
por: Schmid, Tamara, et al.
Publicado: (2016)

Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
por: Birkner, Benjamin, et al.
Publicado: (2020)

The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis
por: Incerti, Devin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pgfnrn7der313bo4a85jnidbt6